ArticleCancer microenvironment : official journal of the International Cancer Microenvironment Society2015
Clinical Impact of Regulatory T cells (Treg) in Cancer and HIV.
Article in Cancer microenvironment : official journal of the International Cancer Microenvironment Society, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Tumor Necrosis Factor Receptor 2 Inhibits HIV-1 Infection by Blocking the Binding of gp120 to CD4.International journal of biological sciences · 2026Article
- Polyamines: the pivotal amines in influencing the tumor microenvironment.Discover oncology · 2024Review
- Evaluation of regulatory T-cells in cancer immunotherapy: therapeutic relevance of immune checkpoint inhibition.Medical oncology (Northwood, London, England) · 2024Review
- Review
- The role of polyamine metabolism in remodeling immune responses and blocking therapy within the tumor immune microenvironment.Frontiers in immunology · 2022Review
- Immunotherapy and predictive immunologic profile: the tip of the iceberg.Medical oncology (Northwood, London, England) · 2021Review
- Clinical Relevance of CD4 Cytotoxic T Cells in High-Risk Neuroblastoma.Frontiers in immunology · 2021Article
- Regulatory T Cells in Cancer Immunotherapy: Basic Research Outcomes and Clinical Directions.Cancer management and research · 2020Review
- T Regulatory Cells and Priming the Suppressive Tumor Microenvironment.Frontiers in immunology · 2019Review
- Regulatory CD4 T cells inhibit HIV-1 expression of other CD4 T cell subsets via interactions with cell surface regulatory proteins.Virology · 2018Article
- The Antitumor Effect of Xihuang Pill on Treg Cells Decreased in Tumor Microenvironment of 4T1 Breast Tumor-Bearing Mice by PI3K/AKT~AP-1 Signaling Pathway.Evidence-based complementary and alternative medicine : eCAM · 2018Article
- Rationale for an Association Between PD1 Checkpoint Inhibition and Therapeutic Vaccination Against HIV.Frontiers in immunology · 2018Article
- Stromal contributions to the carcinogenic process.Molecular carcinogenesis · 2017Review
- Article
- Phenotypic and functional testing of circulating regulatory T cells in advanced melanoma patients treated with neoadjuvant ipilimumab.Journal for immunotherapy of cancer · 2016Article
- Novel technologies and emerging biomarkers for personalized cancer immunotherapy.Journal for immunotherapy of cancer · 2016Review
- IL-21: a pleiotropic cytokine with potential applications in oncology.Journal of immunology research · 2015Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
The role of regulatory T cells, (Treg) in human cancer and HIV-1 infections has been under intense scrutiny. While the lack of a marker specific for human Treg has made it challenging to phenotype these cells, combinations of several markers and functional attributes of Treg have made it possible to assess their contributions to immune homeostasis in health and disease. Treg diversity and their plasticity create a challenge in deciding whether they are beneficial to the host by down-regulating excessive immune activation or are responsible for adverse effects such as suppression of anti-tumor immune responses resulting in promotion of tumor growth. Treg are emerging as active participants in several biochemical pathways involved in immune regulation. This review attempts to integrate current information about human Treg in respect to their activities in cancer and HIV-1. The goal is to evaluate the potential of Treg as targets for future immune or pharmacologic therapies for cancer or HIV-1 infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.